Randomized phase-III-study; Comparing biweekly and tailored epirubicin and cyclophosphamide followed by biweekly tailored docetaxel (dtEC, dtT) (A-arm) vs. three weekly epirubicin and cyclophosphamide, 5-fluorouracil followed by docetaxel (FEC, T) (B-arm) in lymph node positive or high risk lymph node negative breast cancer patients – a continuation of the feasibility part of the SBG 2004-1.

Start: 10/2007
Finish: 09/2011, Follow Up ongoing
Coordinating investigator: Greil, Richard; Salzburg
Sample size: national 450, international 2.000
(Click to enlarge)
ABCSG-25 Design

Link for studyteam-members only

Further information about this trial

Access to these informations only with keyword. If required, please ask the responsible project manager.